Top

Published in:

01-06-2018

Immunohistochemistry in Diagnostic Parathyroid Pathology

Authors: Lori A. Erickson, Ozgur Mete

Published in: Endocrine Pathology | Issue 2/2018

Abstract

Pathologists are usually readily able to diagnose parathyroid tissues and diseases, particularly when they have knowledge of the clinical information, laboratory findings, and radiographic imaging studies. However, the identification of parathyroid tissue or lesions can be difficult in small biopsies, ectopic locations, supranumerary glands, and in some oxyphil/oncocytic lesions. Widely available immunohistochemical studies such as chromogranin-A, synaptophysin, keratin, parathyroid hormone, thyroglobulin, and thyroid transcription factor-1 can help in difficult cases. One of the most difficult diagnostic aspects faced by the pathologist in evaluating parathyroid is distinguishing between parathyroid adenoma, particularly atypical adenoma, and parathyroid carcinoma. Many markers have and continue to be evaluated for diagnostic utility, and are even beginning to be studied for prognostic utility. Single immunohistochemical markers such as parafibromin and Ki-67 are among the most studied and most utilized, but many additional markers have and continue to be evaluated such as galectin-3, PGP9.5, Rb, bcl2, p27, hTERT, mdm2, and APC. Although not widely available in many laboratories, a panel of immunohistochemical markers may prove most useful as an adjunct in the evaluation of challenging parathyroid tumors.

Rosai J, D.R., Carcangiu ML, Frable WJ, Tallini G, Tumors of the thyroid and parathyroid glands. AFIP Atlas of Tumor Pathology, ed. S. SG. Vol. Fascicle 21. 2014, Silver Spring, Maryland, USA: ARP Press. 606.

Tomita, T., Immunocytochemical staining patterns for parathyroid hormone and chromogranin in parathyroid hyperplasia, adenoma, and carcinoma. Endocr Pathol, 1999. 10(2): p. 145–156.PubMedCrossRef

Erickson, L.A., Jin L., Papotti M., Lloyd R.V., Oxyphil parathyroid carcinomas: a clinicopathologic and immunohistochemical study of 10 cases. Am J Surg Pathol, 2002. 26(3): p. 344–349.PubMedCrossRef

Gucer, H. and O. Mete, Endobronchial gangliocytic paraganglioma: not all keratin-positive endobronchial neuroendocrine neoplasms are pulmonary carcinoids. Endocr Pathol, 2014. 25(3): p. 356–358.PubMedCrossRef

Maeda, T., et al., A case of calcitonin-producing parathyroid adenoma with primary hyperparathyroidism. Jpn J Med, 1989. 28(5): p. 640–646.PubMedCrossRef

Chen, L., T.A. Dinh, and A. Haque, Small cell carcinoma of the ovary with hypercalcemia and ectopic parathyroid hormone production. Arch Pathol Lab Med, 2005. 129(4): p. 531–533.PubMed

Williamson, B.R., et al., Poorly differentiated lymphocytic lymphoma with ectopic parathormone production: visulization of metastatic calcification by bone scan. Clin Nucl Med, 1978. 3(10): p. 382–384.PubMedCrossRef

Holtz, G., T.R. Johnson, Jr., and M.E. Schrock, Paraneoplastic hypercalcemia in ovarian tumors. Obstet Gynecol, 1979. 54(4): p. 483–487.PubMed

Goldberg, R.S., D.B. Pilcher, and J.W. Yates, The aggressive surgical management of hypercalcemia due to ectopic parathormone production. Cancer, 1980. 45(10): p. 2652–2654.PubMedCrossRef

10.

Max, M.H. and P.H. Lawrence, Ectopic secretion of parathyroid hormone. Surg Gynecol Obstet, 1980. 150(3): p. 411–418.PubMed

11.

Patel, S. and J.T. Rosenthal, Hypercalcemia in carcinoma of prostate. Its cure by orchiectomy. Urology, 1985. 25(6): p. 627–629.PubMedCrossRef

12.

Buller, R., Taylor K., Burg A.C., Berman M.L., DiSaia P.J., Paraneoplastic hypercalcemia associated with adenosquamous carcinoma of the endometrium. Gynecol Oncol, 1991. 40(1): p. 95–98.PubMedCrossRef

13.

Nakajima, K., Tamai M., Okaniwa S., Nakamura Y., Kobayashi M., Niwa T., Horigome N., Ito N., Suzuki S., Nishio S., Komatsu M., Humoral hypercalcemia associated with gastric carcinoma secreting parathyroid hormone: a case report and review of the literature. Endocr J, 2013. 60(5): p. 557–562.PubMedCrossRef

14.

Koyama, Y., Ishijima H., Ishibashi A., Katsuya T., Ishizaka H., Aoki J., Endo K., Intact PTH-producing hepatocellular carcinoma treated by transcatheter arterial embolization. Abdom Imaging, 1999. 24(2): p. 144–146.PubMedCrossRef

15.

Oliveira, A.M., Tazelaar H.D., Myers J.L., Erickson L.A., Lloyd R.V., Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am J Surg Pathol, 2001. 25(6): p. 815–819.PubMedCrossRef

16.

Agoff, S.N., Lamps L.W., Philip A.T., Amin M.B., Schmidt R.A., True L.D., Folpe A.L., Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol, 2000. 13(3): p. 238–242.PubMedCrossRef

17.

Kaufmann, O. and M. Dietel, Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology, 2000. 36(1): p. 8–16.PubMedCrossRef

18.

Folpe, A.L., Gown A.M., Lamps L.W., Garcia R., Dail D.H., Zarbo R.J., Schmidt R.A., Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol, 1999. 12(1): p. 5–8.PubMed

19.

Fabbro, D., di Loreto C., Stamerra O., Beltrami C.A., Lonigro R., Damante G., TTF-1 gene expression in human lung tumours. Eur J Cancer, 1996. 32A(3): p. 512–517.PubMedCrossRef

20.

Bisceglia, M., Ragazzi M., Galliani C.A., Lastilla G., Rosai J., TTF-1 expression in nephroblastoma. Am J Surg Pathol, 2009. 33(3): p. 454–461.PubMedCrossRef

21.

Nonaka, D., Tang Y., Chiriboga L., Rivera M., Ghossein R., Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol, 2008. 21(2): p. 192–200.PubMedCrossRef

22.

Graham, A.D., A.R. Williams, and D.M. Salter, TTF-1 expression in primary ovarian epithelial neoplasia. Histopathology, 2006. 48(6): p. 764–765.PubMedCrossRef

23.

Pratt, D., Afsar N., Allgauer M., Fetsch P., Palisoc M., Pittaluga S., Quezado M., Re-evaluating TTF-1 immunohistochemistry in diffuse gliomas: Expression is clonedependent and associated with tumor location. Clin Neuropathol, 2017, 36, 263, 271.PubMedCrossRef

24.

Ni, Y.B., Tsang J.Y.S., Shao M.M., Chan S.K., Tong J., To K.F., Tse G.M., TTF-1 expression in breast carcinoma: an unusual but real phenomenon. Histopathology, 2014. 64(4): p. 504–511.PubMedCrossRef

25.

Reis, H.G., et al., [TTF-1 (8G7G3/1) positive colon adenocarcinoma: diagnostic implications]. Pathologe, 2011. 32(4): p. 349–351.PubMedCrossRef

26.

Hakim, S.A. and N.S. Youssef, Diagnostic Utility of Thyroid Transcription Factor-1 in Ovarian Carcinoma and Its Relationship With Clinicopathologic Prognostic Parameters. Appl Immunohistochem Mol Morphol, 2015.

27.

Matoso, A., Singh K., Jacob R., Greaves W.O., Tavares R., Noble L., Resnick M.B., DeLellis R.A., Wang L.J., Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol, 2010. 18(2): p. 142–149.PubMedPubMedCentralCrossRef

28.

Dettmer, M., Kim T.E., Jung C.K., Jung E.S., Lee K.Y., Kang C.S., Thyroid transcription factor-1 expression in colorectal adenocarcinomas. Pathol Res Pract, 2011. 207(11): p. 686–690.PubMedCrossRef

29.

Erickson, L.A., Papouchado B., Dimashkieh H., Zhang S., Nakamura N., Lloyd R.V., Cdx2 as a marker for neuroendocrine tumors of unknown primary sites. Endocr Pathol, 2004. 15(3): p. 247–252.PubMedCrossRef

30.

Marchiori, E., Pelizzo M.R., Herten M., Townsend D.M., Rubello D., Boschin I.M., Specifying the molecular pattern of sporadic parathyroid tumorigenesis-The Y282D variant of the GCM2 gene. Biomed Pharmacother, 2017. 92: p. 843–848.PubMedCrossRef

31.

Nonaka, D., Study of parathyroid transcription factor Gcm2 expression in parathyroid lesions. Am J Surg Pathol, 2011. 35(1): p. 145–151.PubMedCrossRef

32.

Guan, B., Welch J.M., Sapp J.C., Ling H., Li Y., Johnston J.J., Kebebew E., Biesecker L.G., Simonds W.F., Marx S.J., Agarwal S.K., GCM2-Activating Mutations in Familial Isolated Hyperparathyroidism. Am J Hum Genet, 2016. 99(5): p. 1034–1044.PubMedPubMedCentralCrossRef

33.

Laury, A.R., Perets R., Piao H., Krane J.F., Barletta J.A., French C., Chirieac L.R., Lis R., Loda M., Hornick J.L., Drapkin R., Hirsch M.S., A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol, 2011. 35(6): p. 816–826.PubMedCrossRef

34.

Ozcan, A., Shen S.S., Hamilton C., Anjana K., Coffey D., Krishnan B., Truong L.D., PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol, 2011. 24(6): p. 751–764.PubMedCrossRef

35.

Bakshi, N., Kunju L.P., Giordano T., Shah R.B., Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors: diagnostic Implications. Appl Immunohistochem Mol Morphol, 2007. 15(3): p. 310–315.PubMedCrossRef

36.

Han, S.I., Y. Tsunekage, and K. Kataoka, Gata3 cooperates with Gcm2 and MafB to activate parathyroid hormone gene expression by interacting with SP1. Mol Cell Endocrinol, 2015. 411: p. 113–120.PubMedCrossRef

37.

Grigorieva, I.V. and R.V. Thakker, Transcription factors in parathyroid development: lessons from hypoparathyroid disorders. Ann N Y Acad Sci, 2011. 1237: p. 24–38.PubMedCrossRef

38.

Grigorieva, I.V., Mirczuk S., Gaynor K.U., Nesbit M.A., Grigorieva E.F., Wei Q., Ali A., Fairclough R.J., Stacey J.M., Stechman M.J., Mihai R., Kurek D., Fraser W.D., Hough T., Condie B.G., Manley N., Grosveld F., Thakker R.V., Gata3-deficient mice develop parathyroid abnormalities due to dysregulation of the parathyroid-specific transcription factor Gcm2. J Clin Invest, 2010. 120(6): p. 2144–2155.PubMedPubMedCentralCrossRef

39.

Miettinen, M., McCue P.A., Sarlomo-Rikala M., Rys J., Czapiewski P., Wazny K., Langfort R., Waloszczyk P., Biernat W., Lasota J., Wang Z., GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol, 2014. 38(1): p. 13–22.PubMedPubMedCentralCrossRef

40.

Carpten, J.D., Robbins C.M., Villablanca A., Forsberg L., Presciuttini S., Bailey-Wilson J., Simonds W.F., Gillanders E.M., Kennedy A.M., Chen J.D., Agarwal S.K., Sood R., Jones M.P., Moses T.Y., Haven C., Petillo D., Leotlela P.D., Harding B., Cameron D., Pannett A.A., Höög A., Heath H., James-Newton L.A., Robinson B., Zarbo R.J., Cavaco B.M., Wassif W., Perrier N.D., Rosen I.B., Kristoffersson U., Turnpenny P.D., Farnebo L.O., Besser G.M., Jackson C.E., Morreau H., Trent J.M., Thakker R.V., Marx S.J., Teh B.T., Larsson C., Hobbs M.R., HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet, 2002. 32(4): p. 676–680.PubMedCrossRef

41.

Hobbs, M.R., Pole A.R., Pidwirny G.N., Rosen I.B., Zarbo R.J., Coon H., Heath III H., Leppert M., Jackson C.E., Hyperparathyroidism-jaw tumor syndrome: the HRPT2 locus is within a 0.7-cM region on chromosome 1q. Am J Hum Genet, 1999. 64(2): p. 518–525.PubMedPubMedCentralCrossRef

42.

Hendy, G.N. and D.E. Cole, Genetic defects associated with familial and sporadic hyperparathyroidism. Front Horm Res, 2013. 41: p. 149–165.PubMedCrossRef

43.

Iacobone, M., et al., Parafibromin expression, single-gland involvement, and limited parathyroidectomy in familial isolated hyperparathyroidism. Surgery, 2007. 142(6): p. 984–991; discussion 984–91.PubMedCrossRef

44.

Simonds, W.F., Robbins C.M., Agarwal S.K., Hendy G.N., Carpten J.D., Marx S.J., Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab, 2004. 89(1): p. 96–102.PubMedCrossRef

45.

Teh, B.T., Farnebo F., Twigg S., Höög A., Kytölä S., Korpi-Hyövälti E., Wong F.K., Nordenström J., Grimelius L., Sandelin K., Robinson B., Farnebo L.O., Larsson C., Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families. J Clin Endocrinol Metab, 1998. 83(6): p. 2114–2120.PubMed

46.

Kelly, T.G., Shattuck T.M., Reyes-Mugica M., Stewart A.F., Simonds W.F., Udelsman R., Arnold A., Carpenter T.O., Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. J Bone Miner Res, 2006. 21(10): p. 1666–1671.PubMedCrossRef

47.

Szabo, J., et al., Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet, 1995. 56(4): p. 944–950.PubMedPubMedCentral

48.

Yart, A., Gstaiger M., Wirbelauer C., Pecnik M., Anastasiou D., Hess D., Krek W., The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Mol Cell Biol, 2005. 25(12): p. 5052–5060.PubMedPubMedCentralCrossRef

49.

Woodard, G.E., Lin L., Zhang J.H., Agarwal S.K., Marx S.J., Simonds W.F., Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene, 2005. 24(7): p. 1272–1276.PubMedCrossRef

50.

Rozenblatt-Rosen, O., Hughes C.M., Nannepaga S.J., Shanmugam K.S., Copeland T.D., Guszczynski T., Resau J.H., Meyerson M., The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol, 2005. 25(2): p. 612–620.PubMedPubMedCentralCrossRef

51.

Shattuck, T.M., Välimäki S., Obara T., Gaz R.D., Clark O.H., Shoback D., Wierman M.E., Tojo K., Robbins C.M., Carpten J.D., Farnebo L.O., Larsson C., Arnold A., Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med, 2003. 349(18): p. 1722–1729.PubMedCrossRef

52.

Krebs, L.J., T.M. Shattuck, and A. Arnold, HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab, 2005. 90(9): p. 5015–5017.PubMedCrossRef

53.

Cetani, F., Pardi E., Borsari S., Viacava P., Dipollina G., Cianferotti L., Ambrogini E., Gazzerro E., Colussi G., Berti P., Miccoli P., Pinchera A., Marcocci C., Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab, 2004. 89(11): p. 5583–5591.PubMedCrossRef

54.

Tan, M.H., Morrison C., Wang P., Yang X., Haven C.J., Zhang C., Zhao P., Tretiakova M.S., Korpi-Hyovalti E., Burgess J.R., Soo K.C., Cheah W.K., Cao B., Resau J., Morreau H., Teh B.T., Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res, 2004. 10(19): p. 6629–6637.PubMedCrossRef

55.

Gill, A.J., Clarkson A., Gimm O., Keil J., Dralle H., Howell V.M., Marsh D.J., Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol, 2006. 30(9): p. 1140–9.PubMedCrossRef

56.

Juhlin, C.C., Villablanca A., Sandelin K., Haglund F., Nordenstrom J., Forsberg L., Branstrom R., Obara T., Arnold A., Larsson C., Hoog A., Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer, 2007. 14(2): p. 501–512.PubMedCrossRef

57.

Cetani, F., Ambrogini E., Viacava P., Pardi E., Fanelli G., Naccarato A.G., Borsari S., Lemmi M., Berti P., Miccoli P., Pinchera A., Marcocci C., Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol, 2007. 156(5): p. 547–554.PubMedCrossRef

58.

Fernandez-Ranvier, G.G., Khanafshar E., Tacha D., Wong M., Kebebew E., Duh Q.Y., Clark O.H., Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer, 2009. 115(2): p. 334–344.PubMedCrossRef

59.

Juhlin, C.C., Nilsson I.L., Johansson K., Haglund F., Villablanca A., Höög A., Larsson C., Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol, 2010. 21(3): p. 166–177.PubMedCrossRef

60.

Kim, H.K., Oh Y.L., Kim S.H., Lee D.Y., Kang H.C., Lee J.I., Jang H.W., Hur K.Y., Kim J.H., Min Y.K., Chung J.H., Kim S.W., Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma. Head Neck, 2012. 34(2): p. 201–206.PubMedCrossRef

61.

Guarnieri, V., Battista C., Muscarella L.A., Bisceglia M., de Martino D., Baorda F., Maiello E., D’Agruma L., Chiodini I., Clemente C., Minisola S., Romagnoli E., Corbetta S., Viti R., Eller-Vainicher C., Spada A., Iacobellis M., Malavolta N., Carella M., Canaff L., Hendy G.N., Cole D.E.C., Scillitani A., CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort. Cell Oncol (Dordr), 2012. 35(6): p. 411–422.PubMedCrossRef

62.

Wang, O., Wang C.Y., Shi J., Nie M., Xia W.B., Li M., Jiang Y., Guan H., Meng X.W., Xing X.P., Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors. Chin Med J (Engl), 2012. 125(16): p. 2895–2901.

63.

Truran, P.P., Johnson S.J., Bliss R.D., Lennard T.W.J., Aspinall S.R., Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer. World J Surg, 2014. 38(11): p. 2845–2854.PubMedCrossRef

64.

Karaarslan, S., Yurum F.N., Kumbaraci B.S., Pala E.E., Sivrikoz O.N., Akyildiz M., Bugdayci M.H., The Role of Parafibromin, Galectin-3, HBME-1, and Ki-67 in the Differential Diagnosis of Parathyroid Tumors. Oman Med J, 2015. 30(6): p. 421–427.PubMedPubMedCentralCrossRef

65.

Ryhanen, E.M., et al., A nationwide study on parathyroid carcinoma. Acta Oncol, 2017. 56(7): p. 991–1003.PubMedCrossRef

66.

Cetani, F., Banti C., Pardi E., Borsari S., Viacava P., Miccoli P., Torregrossa L., Basolo F., Pelizzo M.R., Rugge M., Pennelli G., Gasparri G., Papotti M., Volante M., Vignali E., Saponaro F., Marcocci C., CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer. Endocr Connect, 2013. 2(4): p. 186–195.PubMedPubMedCentralCrossRef

67.

Howell, V.M., Gill A., Clarkson A., Nelson A.E., Dunne R., Delbridge L.W., Robinson B.G., Teh B.T., Gimm O., Marsh D.J., Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab, 2009. 94(2): p. 434–441.PubMedCrossRef

68.

Howell, V.M., Haven C.J., Kahnoski K., Khoo S.K., Petillo D., Chen J., Fleuren G.J., Robinson B.G., Delbridge L.W., Philips J., Nelson A.E., Krause U., Hammje K., Dralle H., Hoang-Vu C., Gimm O., Marsh D.J., Morreau H., Teh B.T., HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet, 2003. 40(9): p. 657–663.PubMedPubMedCentralCrossRef

69.

Juhlin, C., Larsson C., Yakoleva T., Leibiger I., Leibiger B., Alimov A., Weber G., Höög A., Villablanca A., Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr Relat Cancer, 2006. 13(2): p. 509–523.PubMedCrossRef

70.

Hu, Y., Liao Q., Cao S., Gao X., Zhao Y., Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis. Endocrine, 2016. 54(3): p. 612–619.PubMedCrossRef

71.

Tominaga, Y., Tsuzuki T., Matsuoka S., Uno N., Sato T., Shimabukuro S., Goto N., Nagasaka T., Uchida K., Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease. World J Surg, 2008. 32(5): p. 815–821.PubMedCrossRef

72.

Hahn, M.A. and D.J. Marsh, Nucleolar localization of parafibromin is mediated by three nucleolar localization signals. FEBS Lett, 2007. 581(26): p. 5070–5074.PubMedCrossRef

73.

Panicker, L.M., Zhang J.H., Dagur P.K., Gastinger M.J., Simonds W.F., Defective nucleolar localization and dominant interfering properties of a parafibromin L95P missense mutant causing the hyperparathyroidism-jaw tumor syndrome. Endocr Relat Cancer, 2010. 17(2): p. 513–524.PubMedPubMedCentralCrossRef

74.

Juhlin, C.C., Haglund F., Obara T., Arnold A., Larsson C., Höög A., Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours. Virchows Arch, 2011. 459(1): p. 47–53.PubMedCrossRef

75.

Kumari, N., Chaudhary N., Pradhan R., Agarwal A., Krishnani N., Role of Histological Criteria and Immunohistochemical Markers in Predicting Risk of Malignancy in Parathyroid Neoplasms. Endocr Pathol, 2016. 27(2): p. 87–96.PubMedCrossRef

76.

Bergero, N., de Pompa R., Sacerdote C., Gasparri G., Volante M., Bussolati G., Papotti M., Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol, 2005. 36(8): p. 908–914.PubMedCrossRef

77.

Ozolins, A., Narbuts Z., Vanags A., Simtniece Z., Visnevska Z., Akca A., Wirowski D., Gardovskis J., Strumfa I., Goretzki P.E., Evaluation of malignant parathyroid tumours in two European cohorts of patients with sporadic primary hyperparathyroidism. Langenbecks Arch Surg, 2016. 401(7): p. 943–951.PubMedCrossRef

78.

Inic, Z., Inic M., Jancic S., Paunovic I., Tatic S., Tausanovic K., Zivavljevic V., Zegarac M., Inic I., Dunjdjerovic D., The relationship between proliferation activity and parathyroid hormone levels in parathyroid tumors. J BUON, 2015. 20(2): p. 562–566.PubMed

79.

Lumachi, F., Ermani M., Marino F., Iacobone M., Baldessin M., Cappuzzo G., Zanella S., Favia G., PCNA-LII, Ki-67 immunostaining, p53 activity and histopathological variables in predicting the clinical outcome in patients with parathyroid carcinoma. Anticancer Res, 2006. 26(2A): p. 1305–1308.PubMed

80.

Haven, C.J., van Puijenbroek M., Karperien M., Fleuren G.J., Morreau H., Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma. J Pathol, 2004. 202(1): p. 86–94.PubMedCrossRef

81.

Stojadinovic, A., Hoos A., Nissan A., Dudas M.E., Cordon-Cardo C., Shaha A.R., Brennan M.F., Singh B., Ghossein R.A., Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis. Hum Pathol, 2003. 34(1): p. 54–64.PubMedCrossRef

82.

Kameyama, K., Takami H., Umemura S., Osamura Y.R., Wada N., Sugino K., Mimura T., Ito K., PCNA and Ki-67 as prognostic markers in human parathyroid carcinomas. Ann Surg Oncol, 2000. 7(4): p. 301–4.PubMedCrossRef

83.

Dionisio, P., Stramignoni E., Passarino G., Pucci A., Valenti M., Berto I.M., Barbos P., Cadario A., Gasparri G., Bajardi P., Recurrent secondary hyperparathyroidism due to parathyroid carcinoma: usefulness of Ki-67 immunostaining in the diagnosis of a malignant parathyroid tumor. Nephron, 1996. 74(4): p. 720–723.PubMedCrossRef

84.

Lloyd, R.V., Carney J.A., Ferreiro J.A., Jin L., Thompson G.B., van Heerden J.A., Grant C.S., Wollan P.C., Immunohistochemical Analysis of the Cell Cycle-Associated Antigens Ki-67 and Retinoblastoma Protein in Parathyroid Carcinomas and Adenomas. Endocr Pathol, 1995. 6(4): p. 279–287.PubMedCrossRef

85.

Hosny Mohammed, K., et al., Parafibromin, APC, and MIB-1 Are Useful Markers for Distinguishing Parathyroid Carcinomas From Adenomas. Appl Immunohistochem Mol Morphol, 2016.

86.

Saggiorato, E., Bergero N., Volante M., Bacillo E., Rosas R., Gasparri G., Orlandi F., Papotti M., Galectin-3 and Ki-67 expression in multiglandular parathyroid lesions. Am J Clin Pathol, 2006. 126(1): p. 59–66.PubMedCrossRef

87.

Kruijff, S., Sidhu S.B., Sywak M.S., Gill A.J., Delbridge L.W., Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas. Ann Surg Oncol, 2014. 21(2): p. 426–433.PubMedCrossRef

88.

Erickson, L.A., Jalal S.M., Harwood A., Shearer B., Jin L., Lloyd R.V., Analysis of parathyroid neoplasms by interphase fluorescence in situ hybridization. Am J Surg Pathol, 2004. 28(5): p. 578–584.PubMedCrossRef

89.

Hemmer, S., Wasenius V.M., Haglund C., Zhu Y., Knuutila S., Franssila K., Joensuu H., Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. Am J Pathol, 2001. 158(4): p. 1355–1362.PubMedPubMedCentralCrossRef

90.

Vasef, M.A., Brynes R.K., Sturm M., Bromley C., Robinson R.A., Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol, 1999. 12(4): p. 412–416.PubMed

91.

Hsi, E.D., Zukerberg L.R., Yang W.I., Arnold A., Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab, 1996. 81(5): p. 1736–1739.PubMed

92.

Erovic, B.M., Harris L., Jamali M., Goldstein D.P., Irish J.C., Asa S.L., Mete O., Biomarkers of parathyroid carcinoma. Endocr Pathol, 2012. 23(4): p. 221–231.PubMedCrossRef

93.

Arvai, K., et al., Molecular profiling of parathyroid hyperplasia, adenoma and carcinoma. Pathol Oncol Res, 2012. 18(3): p. 607–614.PubMedCrossRef

94.

Osawa, N., Onoda N., Kawajiri H., Tezuka K., Takashima T., Ishikawa T., Miyauchi A., Hirokawa M., Wakasa K., Hirakawa K., Diagnosis of parathyroid carcinoma using immunohistochemical staining against hTERT. Int J Mol Med, 2009. 24(6): p. 733–741.PubMed

95.

Dotzenrath, C., Teh B.T., Farnebo F., Cupisti K., Svensson A., Toell A., Goretzki P., Larsson C., Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors? J Clin Endocrinol Metab, 1996. 81(9): p. 3194–3196.PubMedCrossRef

96.

Cryns, V.L., Thor A., Xu H.J., Hu S.X., Wierman M.E., Vickery Jr A.L., Benedict W.F., Arnold A., Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med, 1994. 330(11): p. 757–761.PubMedCrossRef

97.

Shattuck, T.M., Kim T.S., Costa J., Yandell D.W., Imanishi Y., Palanisamy N., Gaz R.D., Shoback D., Clark O.H., Monchik J.M., Wierman M.E., Hollenberg A., Tojo K., Chaganti R.S.K., Arnold A., Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clin Endocrinol (Oxf), 2003. 59(2): p. 180–189.CrossRef

98.

Subramaniam, P., S. Wilkinson, and J.J. Shepherd, Inactivation of retinoblastoma gene in malignant parathyroid growths: a candidate genetic trigger? Aust N Z J Surg, 1995. 65(10): p. 714–716.PubMedCrossRef

99.

Erickson, L.A., Jin L., Wollan P., Thompson G.B., van Heerden J.A., Lloyd R.V., Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein. Am J Surg Pathol, 1999. 23(3): p. 288–295.PubMedCrossRef

100.

Witteveen, J.E., Hamdy N.A.T., Dekkers O.M., Kievit J., van Wezel T., Teh B.T., Romijn J.A., Morreau H., Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma. Mod Pathol, 2011. 24(5): p. 688–697.PubMedCrossRef

101.

Duan, K., Mete, O., Familial Hyperparathyroidism Syndromes. Diagnostic Histopathology, 2016. 22(3): p. 92–100.CrossRef

102.

Gill, A.J., Lim G., Cheung V.K.Y., Andrici J., Perry-Keene J.L., Paik J., Sioson L., Clarkson A., Sheen A., Luxford C., Elston M.S., Meyer-Rochow G.Y., Nano M.T., Kruijff S., Engelsman A.F., Sywak M., Sidhu S.B., Delbridge L.W., Robinson B.G., Marsh D.J., Toon C.W., Chou A., Clifton-Bligh R.J., Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features. Am J Surg Pathol, 2018, 1.

Title: Immunohistochemistry in Diagnostic Parathyroid Pathology
Authors: Lori A. Erickson
Ozgur Mete
Publication date: 01-06-2018
Publisher: Springer US
Published in: Endocrine Pathology / Issue 2/2018
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI: https://doi.org/10.1007/s12022-018-9527-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Old, New, and Emerging Immunohistochemical Markers in Pheochromocytoma and Paraganglioma

Immunohistochemical Biomarkers in Thyroid Pathology

Fit-for-Purpose Immunohistochemical Biomarkers

Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms

Immunohistochemical Biomarkers of Mesenchymal Neoplasms in Endocrine Organs: Diagnostic Pitfalls and Recent Discoveries

Immunohistochemical Biomarkers in Pituitary Pathology

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage